PBH on NYSE

Prestige Brands

Logo: Prestige Brands Holdings, Inc., Public domain, via Wikimedia Commons5

American company that markets and distributes over-the-counter healthcare

Prestige Consumer Healthcare Inc. (formerly Prestige Brands, Inc.) is an American company that markets and distributes over-the-counter healthcare and household cleaning products.3 From Wikipedia, CC BY-SA 4.0

$49.38 up 0.97 (2.01%)Price as of Oct 15, 2026 at 17:33 UTC

Last updated Oct 18, 2026.

Overview

$1.1BRevenue, fiscal 20266
$190.3MNet income, fiscal 20266
1996Founded1

Compare with Acadia Pharmaceuticals, Nasus Pharma Ltd or Actavis, or pick any stock.

  • TickerPBH on NYSE1
  • IndustryPharmaceutical Preparations1
  • HeadquartersTarrytown1
  • Websitewww.prestigebrands.com
  • Legal formDelaware corporation1

Prestige Consumer Healthcare Inc. (formerly Prestige Brands, Inc.) is an American company that markets and distributes over-the-counter healthcare and household cleaning products. It was formed by the merger of Medtech Products, Inc., Prestige Brands International, and the Spic and Span Company in 1996. The company is headquartered in Tarrytown, New York and operates a manufacturing facility in Lynchburg, Virginia.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

54.7%Gross margin6
28.4%Operating margin6
17.5%Net margin6
-4.3%Revenue growth, 20266
10.1%Return on equity6
0.53×Debt to equity6
$246.4MFree cash flow6

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Gastrointestinal brought in 24% of the revenue Prestige Brands broke down this way in fiscal 2026.

  1. Gastrointestinal$259.8M624%up 2% from 2025
  2. Women's Health$227.8M621%down 4% from 2025
  3. Eye and Ear Care$142.9M613%down 22% from 2025
  4. Dermatologicals$125.9M612%down 2% from 2025
  5. Analgesics$113.9M610%down 3% from 2025
  6. Cough and Cold$101.9M69%down 4% from 2025
  7. Oral Care$101.1M69%up 6% from 2025
  8. Other OTC$15.4M61%up 12% from 2025
  9. Product and Service, Other$4.0M60%up 235% from 2025
Products and services by year
Products and services202420252026
Gastrointestinal$231.6M$255.9M$259.8M
Women's Health$240.4M$236.8M$227.8M
Eye and Ear Care$179.4M$183.3M$142.9M
Dermatologicals$129.1M$128.9M$125.9M
Analgesics$117.5M$117.7M$113.9M
Cough and Cold$119.0M$106.2M$101.9M
Oral Care$96.3M$95.0M$101.1M
Other OTC$12.0M$13.8M$15.4M
Product and Service, Other$311.0K$1.2M$4.0M

Business segments

North American OTC Healthcare brought in 84% of the revenue Prestige Brands broke down this way in fiscal 2026.

  1. North American OTC Healthcare$913.6M684%down 5% from 2025
  2. International OTC Healthcare$175.1M616%down 1% from 2025
Business segments by year
Business segments202420252026
North American OTC Healthcare$958.3M$960.0M$913.6M
International OTC Healthcare$167.1M$177.8M$175.1M

Regions

United States brought in 78% of the revenue Prestige Brands broke down this way in fiscal 2026.

  1. United States$850.4M678%down 5% from 2025
  2. Outside the United States$238.3M622%down 1% from 2025
Regions by year
Regions202420252026
United States$886.5M$897.5M$850.4M
Outside the United States$238.9M$240.2M$238.3M

Where the money goes

Where each dollar of revenue went, fiscal 2026

  • Cost of revenue45¢$493.1M
  • Other costs31¢$338.1M
  • Income tax6¢$67.2M
  • Profit17¢$190.3M

Out of $1.1B in revenue.6

Where each dollar of operating cash went, fiscal 2026

  • Capital spending4¢$11.2M
  • Share buybacks61¢$156.3M
  • Kept or used elsewhere35¢$90.2M

Out of $257.6M of cash from operations.6

Financial statements

Revenue891011126$1.1B in 2026+12% since 2019
0$500.0M$1.0B$1.5B2019: $975.8M$975.8M20192020: $963.0M$963.0M2020−1%2021: $943.4M$943.4M2021−2%2022: $1.1B$1.1B2022+15%2023: $1.1B$1.1B2023+4%2024: $1.1B$1.1B2024−0%2025: $1.1B$1.1B2025+1%2026: $1.1B$1.1B2026−4%
Gross profit891011126$595.6M in 2026+7% since 2019
0$200.0M$400.0M$600.0M$800.0M2019: $555.6M$555.6M20192020: $552.2M$552.2M2020−1%2021: $547.5M$547.5M2021−1%2022: $620.6M$620.6M2022+13%2023: $625.3M$625.3M2023+1%2024: $624.4M$624.4M2024−0%2025: $634.5M$634.5M2025+2%2026: $595.6M$595.6M2026−6%
Operating income891011126$309.4M in 2026+358% since 2019
-$100.0M0$100.0M$200.0M$300.0M$400.0M2019: $67.5M$67.5M20192020: $291.2M$291.2M2020+331%2021: $297.4M$297.4M2021+2%2022: $329.9M$329.9M2022+11%2023: -$22.4M-$22.4M20232024: $342.4M$342.4M20242025: $336.8M$336.8M2025−2%2026: $309.4M$309.4M2026−8%
Net income891011126$190.3M in 2026
-$100.0M0$100.0M$200.0M$300.0M2019: -$35.8M-$35.8M20192020: $142.3M$142.3M20202021: $164.7M$164.7M2021+16%2022: $205.4M$205.4M2022+25%2023: -$82.3M-$82.3M20232024: $209.3M$209.3M20242025: $214.6M$214.6M2025+3%2026: $190.3M$190.3M2026−11%

Every line of the income statement as filed: the last 3 fiscal years, latest first.6

Period ending2026-03-312025-03-312024-03-31
Total revenues$1.1B$1.1B$1.1B
Cost of sales excluding depreciation$482.8M$494.4M$492.8M
Cost of sales depreciation$10.3M$8.9M$8.1M
Cost of sales$493.1M$503.3M$500.9M
Gross profit$595.6M$634.5M$624.4M
Advertising and marketing$148.8M$155.7M$153.3M
General and administrative$116.4M$108.2M$106.2M
Depreciation and amortization$20.9M$21.3M$22.6M
Goodwill and tradename impairment$0$12.5M$0
Total operating expenses$286.2M$297.7M$282.0M
Operating income$309.4M$336.8M$342.4M
Interest expense, net$42.3M$47.6M$67.2M
Other expense (income), net$9.6M$5.0M-$756.0K
Total other expense, net$51.9M$52.6M$66.4M
Income before income taxes$257.5M$284.2M$276.0M
Provision for income taxes$67.2M$69.6M$66.7M
Net income$190.3M$214.6M$209.3M
Basic (in USD per share)$3.93$4.32$4.21
Diluted (in USD per share)$3.91$4.29$4.17
Basic (in shares)48.5M shares49.7M shares49.8M shares
Diluted (in shares)48.7M shares50.1M shares50.2M shares
Currency translation adjustments$9.4M-$3.1M-$2.9M
Unrecognized net (loss) gain on pension plans-$96.0K-$81.0K$9.0K
Total other comprehensive income (loss)$9.3M-$3.2M-$2.9M
Comprehensive income$199.6M$211.4M$206.4M

Compare Prestige Brands with another company

The story

Prestige Brands Holdings, Inc. was established in 1999 to acquire, revitalize, and line extend leading, often neglected but healthy brands that were considered non-core at major consumer products companies. In 2004, MidOcean Partners sold Prestige Brands to GTCR Golder Rauner.

Acquisitions

The company acquired Blacksmith Brands' portfolio of five brands in 2010.

In December 2011, the company agreed to purchase 17 brands from GlaxoSmithKline including BC Powder, Beano, Ecotrin, Fiber Choice, Goody's Powder, Sominex and Tagamet for $660 million.

In 2013, Prestige Brands Holdings, Inc. acquired Care Pharmaceuticals of Bondi Junction, New South Wales, Australia, a privately held marketer and distributor of over-the-counter (OTC) healthcare brands for children and adults.

In 2014, the company purchased Hydralyte in Australia and New Zealand from the Hydration Pharmaceuticals Trust of Victoria, Australia. Hydralyte is the leading oral rehydration product in Australia and New Zealand.

In April 2014, Prestige Brands Holdings, Inc. announced that it has entered into a definitive agreement to acquire Insight Pharmaceuticals Corporation, a marketer and distributor of feminine care and other over-the-counter healthcare products, for $750 million in cash.

In November 2015, Prestige Brands Holdings, Inc. announced that it has entered into a definitive agreement to acquire DenTek Oral Care Inc. (DenTek), a privately held marketer and distributor of oral care products for $225 million in cash.

In December 2016, Prestige Brands Holdings, Inc. agreed to buy C.B. Fleet Co. from private-equity firm Gryphon Investors for about $825 million.

Read the full text

In July 2021, consumer health business assets were acquired from Akorn Operating Company, LLC for $228.9 million adding TheraTears and other products to their brands.

Divestitures

In 2009, Prestige sold its Denorex and Prell brands of shampoo. It has since divested Fiber Choice, PediaCare, New-Skin, and Dermoplast (2016).

In 2018, Prestige sold off their household cleaning supply division.

From Wikipedia’s article on Prestige Consumer Healthcare, shared under CC BY-SA 4.0.7

Leadership

Who has led Prestige Brands, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (41)

Products and brands

Prestige Consumer Healthcare owns many over-the counter medicines and products, including:

From Wikipedia’s article on Prestige Consumer Healthcare, shared under CC BY-SA 4.0.7

Timeline

  1. May 11, 2016New chief executive Ronald M. Lombardi becomes CEO17
  2. Aug 22, 2011New chief executive Charles Hinkaty becomes CEO18
  3. Sep 4, 2009New chief executive Matthew Mannelly becomes CEO19
  4. Jan 19, 2007New chief executive Mark Pettie becomes CEO20
  5. May 23, 2006New chief executive Frank Palantoni becomes CEO21
  6. 1996Founded Founded1

Filings

274 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 30 major events, 160 insider forms, 22 large holders, 42 other. The latest 20:

  1. Aug 14, 20268-K EDGAR
  2. Aug 6, 202610-Q EDGAR
  3. Aug 6, 20268-K EDGAR
  4. Aug 5, 20264 OWNERSHIP DOCUMENT EDGAR
  5. Aug 5, 20264 OWNERSHIP DOCUMENT EDGAR
  6. Aug 5, 20264 OWNERSHIP DOCUMENT EDGAR
  7. Aug 5, 20264 OWNERSHIP DOCUMENT EDGAR
  8. Aug 5, 20264 OWNERSHIP DOCUMENT EDGAR
  9. Jul 15, 20268-K EDGAR
  10. Jul 9, 20268-K/A EDGAR
  11. Jul 7, 2026SCHEDULE 13G/A EDGAR
  12. Jul 6, 20268-K EDGAR
  13. Jun 30, 20268-K/A EDGAR
  14. Jun 29, 2026ARS ANNUAL REPORT TO SECURITY HOLDERS EDGAR
  15. Jun 29, 2026DEF 14A EDGAR
  16. Jun 16, 20268-K EDGAR
  17. May 14, 202610-K EDGAR
  18. May 14, 20264/A OWNERSHIP DOCUMENT EDGAR
  19. May 13, 20268-K EDGAR
  20. May 12, 20264 OWNERSHIP DOCUMENT EDGAR

The 274 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 22 such filings since October 2021, the latest 10:

  1. Jul 7, 2026SCHEDULE 13G/A
  2. Apr 30, 2026SCHEDULE 13G
  3. Apr 29, 2026SCHEDULE 13G
  4. Mar 27, 2026SCHEDULE 13G/A
  5. Feb 13, 2026SCHEDULE 13G/A
  6. Nov 14, 2025SCHEDULE 13G
  7. Aug 13, 2025SCHEDULE 13G/A
  8. Feb 7, 2025SCHEDULE 13G/A
  9. Jan 23, 2025SCHEDULE 13G/A
  10. Nov 8, 2024SC 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.7,831,333$370.2M0.0%+442,843
Ariel Investments, LLC4,868,711$230.1M2.3%+594,385
Vanguard Portfolio Management LLC2,825,340$133.6M0.0%+21,512
Dimensional Fund Advisors LP2,661,291$125.8M0.0%−11,486
Fuller & Thaler Asset Management, Inc.2,331,821$110.2M0.3%New
Vanguard Capital Management LLC2,136,944$101.0M0.0%+43,951
State Street Corp2,116,513$100.0M0.0%+145,532
Brandes Investment Partners, LP2,051,060$97.0M0.7%+1,196,941
Kayne Anderson Rudnick Investment Management LLC1,872,023$88.5M0.3%−330,583
Geode Capital Management, LLC1,571,742$74.3M0.0%+111,707
Allspring Global Investments Holdings, LLC1,271,950$61.3M0.1%−286,154
Morgan Stanley1,243,931$58.8M0.0%−113,539
Nordea Investment Management Ab828,628$39.3M0.0%+229,253
Northern Trust Corp773,449$36.6M0.0%+23,144
Westwood Holdings Group Inc750,445$35.5M0.3%−369,270
Rice Hall James & Associates, LLC689,692$32.6M1.6%+168,070
Manufacturers Life Insurance Company, The658,659$31.1M0.0%+185,508
Charles Schwab Investment Management Inc654,174$30.9M0.0%−87,975
UBS Group AG638,605$30.2M0.0%+246,396
Massachusetts Financial Services Co /ma/629,836$29.8M0.0%+31,810
Boston Trust Walden Corp609,949$28.8M0.2%−33,391
Goldman Sachs Group Inc586,536$27.7M0.0%+128,918
Citadel Advisors LLC564,157$26.7M0.0%+380,717
Bank Of America Corp /de/555,894$26.3M0.0%+8,452
Raymond James Financial Inc464,353$21.9M0.0%−92,107

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
    Yahoo FinancePBH quote
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65